NRG-GY018
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Closed to Enrollment, Patients in Follow-Up